Ticker Details
Axon Holdings S.A. Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.
IPO Date:	June 11, 2015
Sector:	Industrials
Industry:	Aerospace and Defense
Market Cap:	$34.47B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$3.23 | 2.39%
Avg Daily Range (30 D):	$12.49 | 2.47%
Avg Daily Range (90 D):	$11.97 | 2.09%

Institutional Daily Volume
Avg Daily Volume:	.62M
Avg Daily Volume (30 D):	.84M
Avg Daily Volume (90 D):	.75M

Trade Size
Avg Trade Size (Sh.):	66
Avg Trade Size (Sh.) (30 D):	21
Avg Trade Size (Sh.) (90 D):	20

Institutional Trades
Total Institutional Trades:	3,507
Avg Institutional Trade:	$16.47M
Avg Institutional Trade (30 D):	$29.46M
Avg Institutional Trade (90 D):	$33.63M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$28.82M
Avg Closing Trade (30 D):	$53.54M
Avg Closing Trade (90 D):	$61.19M
Avg Closing Volume:	86.7K

News

Feb 13, 2026 @ 3:37 PM Amazon's Lost Puppy Super Bowl Commercial Backfire... Source: Chris Katje

Feb 1, 2026 @ 7:31 PM UnitedHealth, Trade Desk, And Unity Are Among Top ... Source: Nabaparna Bhattacharya

Jan 13, 2026 @ 3:00 PM LVT Ranked No. 1 Innovative Leader in 2025 Frost R... Source: Not Specified

Jan 8, 2026 @ 5:14 AM Is Axon (AXON) Stock a Buy in 2026? Source: Jennifer Saibil

Jan 4, 2026 @ 8:55 PM How Trump Moved Stocks In 2025: Crypto, Drones, He... Source: Erica Kollmann

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$-.03	$.46
Diluted EPS		$-.03	$.44
Revenue		$710.64M	$668.54M
Gross Profit		$427.35M	$403.74M
Net Income / Loss		$-2.19M	$36.12M
Operating Income / Loss		$-2.13M	$-1.04M
Cost of Revenue		$283.29M	$264.8M
Net Cash Flow		$808.68M	$-477.3M
PE Ratio

Splits
Sep 28, 2007	1:600
Nov 30, 2004	2:1
Apr 30, 2004	2:1
Feb 11, 2004	3:1